Welcome to our dedicated page for Rentokil Initial Plc SEC filings (Ticker: RTO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Rentokil Initial plc (NYSE: RTO) provides access to the company’s U.S. regulatory disclosures, including its annual report on Form 20-F and current reports on Form 6-K. As a foreign private issuer and UK-listed company, Rentokil Initial uses these filings to share information with U.S. investors about its global pest control, hygiene and wellbeing operations.
Form 20-F contains detailed information about the group’s business activities, risk factors, governance and financial reporting. For a company operating in around 90 countries and employing more than 60,000 people, this document is a key resource for understanding the structure and scope of its pest control and hygiene services, as well as its North American operations under the Rentokil Terminix brand.
Form 6-K current reports are used to furnish important information that Rentokil Initial releases in other markets. Examples in the available data include notifications of major shareholdings, directorate changes and announcements that the Annual Report and Financial Statements and AGM notices have been filed with the UK Financial Conduct Authority and made available via the National Storage Mechanism. Some 6-K filings also cover matters such as director and related party share dealings in the company’s American Depositary Shares.
On Stock Titan, these filings are updated as they are released through EDGAR and can be paired with AI-powered summaries to help explain complex sections in clearer language. This can be particularly useful when reviewing topics such as major shareholder notifications, governance changes or the structure of Rentokil Initial’s ADS programme, where each ADS represents five ordinary shares. The filings page is therefore a central reference point for investors and researchers seeking a regulatory view of RTO’s global business services operations.
Rentokil Initial plc filed a Form 6-K reporting a UK TR-1 notification of major holdings by GIC Private Limited. As of 16/10/2025, GIC’s total voting rights were 5.908063%, down from 6.103843% previously, representing 149,240,021 voting rights.
The position comprises 5.620219% attached to shares and 0.287844% through financial instruments (lent securities). Within the share component, GIC reported 4.469159% direct voting rights (112,892,730) and 1.151060% indirect voting rights (29,076,235), totaling 141,968,965 voting rights attached to shares. Financial instruments cover 7,271,056 voting rights, or 0.287844%.
Rentokil Initial plc declared an interim dividend of 4.15 US cents per ordinary share for the six months ended 30 June 2025, announced in respect of the payment on 31 July 2025. The pence sterling amount was set using the average closing spot exchange rates over the three working days from 20 August 2025, producing an applicable rate of £1 = US$1.3463 and a payable amount of 3.08 pence per ordinary share. The dividend will be paid on 22 September 2025 to shareholders on the register at the close of business on 15 August 2025.
Janus Henderson Group plc reports beneficial ownership of common stock in Rentokil Initial plc totaling 142,879,790 shares, representing approximately 5.7% of the class. The filing identifies the reporting person as an investment adviser (Type IA, HC) and discloses that certain indirect subsidiaries (including JHIUS) may be deemed beneficial owners of a portion of the position, with JHIUS shown as beneficially owning 127,751,451 shares (about 5.1% of the class).
The filing states these securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control of the issuer. A power of attorney authorizes named company employees to execute filings on Janus Henderson's behalf.
H1 2025 highlights: Revenue from continuing operations grew 3.1 % YoY to $3.36 bn (1.6 % organic). Adjusted operating profit slipped 4.5 % to $511 m, cutting margin 120 bps to 15.2 %. Adjusted PBT was $418 m (-7.8 %) and adjusted EPS 12.46 c (-11 %). Statutory PBT fell 26 % to $216 m after a $79 m increase in the termite-damage provision.
Cash & capital: Free cash flow rose 31 % to $282 m with 93 % conversion (vs 80 % guidance). Net debt climbed to $4.22 bn, or 2.8× adjusted EBITDA, largely due to bond financing and FX; liquidity headroom is $2.0 bn. Interim dividend maintained at 4.15 c.
Operating trends: North America revenue +2.0 % (organic +1.1 %) but adjusted profit -7.3 % and margin 16.9 %. International revenue +5.1 %, adjusted profit +4.6 %, margin steady at 19.3 %. Group organic growth improved in Q2, with North America organic growth 1.4 % versus 0.7 % in Q1. Integration of Terminix continues; ~$100 m cost-reduction target and >20 % NA margin post-2026 reiterated. FY-25 outlook and technical guidance unchanged.
On 24 Jul 2025 sovereign wealth fund GIC Private Limited crossed a disclosure threshold in Rentokil Initial plc, triggering this Form 6-K/TR-1 major-holdings notice. GIC now controls 6.494659 % of Rentokil’s voting rights, equal to 164.06 million votes. The stake consists of 5.940639 % (150.06 m votes) held via ordinary shares and 0.554020 % (13.99 m votes) linked to security-lending arrangements.
The change is primarily a reclassification of part of the holding as “security lending” rather than a meaningful purchase or sale; the previously reported total was 6.500133 %. No financial results, guidance or operational updates are included. The filing, dated 28 Jul 2025, fulfils UK Disclosure & Transparency Rule 5 obligations and has limited direct impact on Rentokil’s fundamentals.